{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:01:21Z","timestamp":1791169281378,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2006,10,30]],"date-time":"2006-10-30T00:00:00Z","timestamp":1162166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Autoantibody production in patients with systemic lupus erythematosus (SLE) is associated with abnormalities of B cell function and phenotype. Clinical responses to B cell depletion therapy (BCDT), based on rituximab, are encouraging. Therefore, we undertook this study to investigate the effect of BCDT on antibody profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Serial sera from 16 patients with active, refractory SLE were assayed for antinucleosome antibodies, anti\u2013double\u2010stranded DNA (anti\u2010dsDNA), anti\u2013extractable nuclear antigen, anti\u2013tetanus toxoid, and antibodies to pneumococcal capsular polysaccharide for at least 1 year following BCDT. Anti\u2010dsDNA antibodies derived from the V\n                      <jats:sub>H<\/jats:sub>\n                      4.34 immunoglobulin germ line gene (9G4+) were also measured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients achieved peripheral B cell depletion and improved clinically for at least 3 months. Antinucleosome and anti\u2010dsDNA antibodies decreased to a mean \u00b1 SD of 64 \u00b1 37% and 38 \u00b1 33% of baseline values, respectively, by 6\u20138 months post\u2010BCDT. Levels of other autoantibodies and antimicrobial antibodies were generally unchanged. In the 9 of 16 patients who were still well at 1 year, anti\u2010dsDNA antibodies fell to 42 \u00b1 36% of baseline values at 6\u20138 months and to 37 \u00b1 33% at 10\u201314 months. In patients who had disease flares within 1 year of BCDT, levels of these antibodies decreased to 60 \u00b1 40% and 83 \u00b1 93% of baseline values at 6\u20138 months and at 10\u201314 months, respectively. Circulating anti\u2010dsDNA antibodies were positive for 9G4 expression in 4 of 6 patients tested, and flares in 2 of these patients were accompanied by rises in 9G4+ anti\u2010dsDNA antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These observations suggest that B cell clones committed to producing antinucleosome and anti\u2010dsDNA antibodies, including the V\n                      <jats:sub>H<\/jats:sub>\n                      4.34 subpopulation of anti\u2010dsDNA antibodies, have a relatively rapid turnover compared with B cell clones producing other antibodies. There was also a trend toward a greater and more sustained decrease in anti\u2010dsDNA antibodies in patients with clinical benefit lasting &gt;1 year.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.22211","type":"journal-article","created":{"date-parts":[[2006,10,30]],"date-time":"2006-10-30T14:24:42Z","timestamp":1162218282000},"page":"3612-3622","source":"Crossref","is-referenced-by-count":198,"title":["B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles"],"prefix":"10.1002","volume":"54","author":[{"given":"G.","family":"Cambridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Leandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Teodorescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,30]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh446"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1838"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000082086"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830220523"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.0109.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.6.3422"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.2.762"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118643"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb06034.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/S0270-9295(03)00135-9"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330505"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<76::AID-ANR10>3.0.CO;2-I"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20103"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1994.tb03431.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1993.1066"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24179"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.9.566"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei080"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh624"},{"key":"e_1_2_5_23_2","first-page":"1761","article-title":"Information on diagnosis and management of systemic lupus erythematosus derived from the routine measurement of 8 nuclear autoantibodies","volume":"30","author":"Ignat GP","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(99)04041-0"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00809.x"},{"key":"e_1_2_5_26_2","volume-title":"The immunological basis for immunization series: module 3, tetanus","author":"Galazka AM","year":"1993"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02232.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20858"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2005.09.009"},{"key":"e_1_2_5_31_2","first-page":"642","article-title":"Role of complement in innate and autoimmunity","volume":"18","author":"Seelen MA","year":"2005","journal-title":"J Nephrol"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10764"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.817"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20592"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983377"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.883"},{"key":"e_1_2_5_37_2","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.4049\/jimmunol.157.6.2449","article-title":"Use of phage surface expression to analyze regions of human V4\u201034(VH4\u201021)\u2010encoded IgG autoantibody required for recognition of DNA: no involvement of the 9G4 idiotope","volume":"157","author":"Mockridge CI","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.10.876"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.22211","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.22211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T12:24:34Z","timestamp":1695903874000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.22211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,30]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1002\/art.22211"],"URL":"https:\/\/doi.org\/10.1002\/art.22211","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,30]]}}}